Study of Drug Resistance in Cancer Cell Lines
Author Information
Author(s): SL Davies, J Bergh, AL Harris, ID Hickson
Primary Institution: Imperial Cancer Research Fund Laboratories, University of Oxford
Hypothesis
The study investigates the relationship between gene expression and resistance to topoisomerase II inhibitors in cancer cell lines.
Conclusion
The resistance mechanisms for cleavable complex-forming topoisomerase II inhibitors and ICRF-159 are distinct, with some cell lines showing collateral sensitivity to ICRF-159.
Supporting Evidence
- Overexpression of P-glycoprotein and MRP did not confer resistance to ICRF-159.
- Marked down-regulation of topoisomerase IIa was associated with collateral sensitivity to ICRF-159.
- Cell lines selected for resistance to cleavable complex-forming topo II inhibitors were not cross-resistant to ICRF-159.
Takeaway
This study looked at how certain cancer cells resist drugs and found that some cells can actually be more sensitive to a different drug.
Methodology
The study used various human cancer cell lines and assessed their sensitivity to ICRF-159 through clonogenic and growth inhibition assays.
Limitations
The study does not provide a consistent pattern of altered topoisomerase II gene expression across all resistant cell lines.
Want to read the original?
Access the complete publication on the publisher's website